Company news
VivoSim Labs, Inc. news in 2026
VivoSim Labs, Inc.'s news releases, calls and decks from 2026, newest first.
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
October 21, 2026
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
October 7, 2026
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 1, 2026
VivoSim Provides Financial and Listing Compliance Update
August 6, 2026
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
July 16, 2026
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
July 15, 2026
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
June 29, 2026
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
April 28, 2026
VivoSim Announces Pricing of up to a $4 Million Public Offering
March 31, 2026
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
March 23, 2026
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
March 3, 2026
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
February 11, 2026
NIO Inc. Announces Profit Alert for the Fourth Quarter of 2025
February 5, 2026
NIO Inc. Provides January 2026 Delivery Update
February 1, 2026
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
January 29, 2026
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
January 6, 2026
Decks in 2026
- Investor Presentation (2026)
Investor deck · 22 slides · 2026